LivaNova PLC (LIVN)
NASDAQ:LIVN
Want to see LIVN full AI Analyst Report?
Earnings Data
Report Date
Jul 29, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.09Last Year’s EPS
1.05Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call delivered multiple material positive developments: double-digit Q1 revenue growth, upward revisions to full-year revenue and EPS guidance, regulatory approval and robust clinical evidence in OSA, meaningful reimbursement improvement for VNS in the U.S., strong cardiopulmonary momentum (Essenz upgrade and manufacturing expansion) and clinical differentiation (PolySync). Headwinds exist—near-term cash and free cash flow pressures driven by higher capex, working capital and a one-time bonus payout; modest gross margin compression; ongoing third-party supply constraints and reimbursement/coding uncertainty for HGNS and DTTD—which the company is actively addressing. On balance, the positives (revenue/earnings upgrades, regulatory/clinical milestones, market share gains and manufacturing expansion plans) outweigh the lowlights, indicating strong operational momentum while the company invests for growth and manages known near-term pressures.Company Guidance
Top-line Growth and Upgraded 2026 Revenue Guidance
Consolidated revenue of $362 million in Q1 2026, up 11% year-over-year on a constant currency basis; updated full-year 2026 revenue growth guidance increased to 7%–8% from 6%–7%.
Cardiopulmonary Segment Strength
Cardiopulmonary revenue of $209 million in Q1, up 14% year-over-year; heart-lung machine (HLM) revenue grew in the high teens and consumables grew in the mid-teens; full-year cardiopulmonary revenue guidance raised to 8.5%–9.5% (from 7%–8%).
Essenz Upgrade Momentum and Manufacturing Upside
Essenz penetration expected to represent ~80% of annual HLM placements in 2026 vs ~55% in 2025; company expects manufacturing output to increase low double-digits in 2026 and plans new manufacturing line to go live in H2 2026 to accelerate oxygenator output.
Epilepsy Business Acceleration and Reimbursement Win
Epilepsy revenue increased 8% year-over-year (Europe & RoW +12%, U.S. +7%); U.S. Medicare outpatient payments for VNS therapy increased ~48% for new patient implants and ~47% for end-of-service procedures effective Jan 1, 2026; full-year epilepsy revenue guidance raised to 6%–7% (from 5.5%–6.5%).
Regulatory and Clinical Milestones in OSA
Received FDA PMA for the aura6000 system (first FDA-approved HGNS device without CCC-related contraindication or warning); full 12-month OSPREY RCT results published in Annals of Internal Medicine demonstrating clinically meaningful and sustained improvements.
PolySync Efficacy and Clinical Differentiation
PolySync titration algorithm converted over 50% of OSPREY nonresponders into responders; cumulative responder rate approaching ~80% across the OSPREY population following PolySync, strengthening competitive positioning ahead of launch.
Improved Profitability Metrics and EPS Upgrade
Adjusted operating income of $71 million in Q1 (vs $65 million prior year); adjusted operating margin ~20% in Q1 and full-year margin forecast 20%–21%; adjusted diluted EPS $0.98 in Q1 vs $0.88 prior year; 2026 adjusted diluted EPS guidance raised to $4.20–$4.30 (approx. 9% growth at midpoint).
Balance Sheet Improvements and Debt Reduction
Cash balance $540 million and total debt $288 million as of March 31, 2026 (debt reduced from $377 million at year-end 2025) following early repayment of $98 million in term facilities.
LIVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LIVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $57.59 | $66.26 | +15.05% |
Feb 25, 2026 | $69.05 | $70.29 | +1.80% |
Nov 05, 2025 | $53.94 | $50.81 | -5.80% |
Aug 06, 2025 | $42.61 | $47.36 | +11.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does LivaNova PLC (LIVN) report earnings?
LivaNova PLC (LIVN) is schdueled to report earning on Jul 29, 2026, Before Open (Confirmed).
What is LivaNova PLC (LIVN) earnings time?
LivaNova PLC (LIVN) earnings time is at Jul 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LIVN EPS forecast?
LIVN EPS forecast for the fiscal quarter 2026 (Q2) is 1.09.